
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Rethinking Post-Colonoscopy Colorectal Cancer Risk</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Rethinking Post-Colonoscopy Colorectal Cancer Risk</strong></summary>
            <div>
                <ul><li>Study by van Roermund NS, Coupé VMH, Spaander MCW, et al. Published in Clinical Gastroenterology and Hepatology (2025).</li><li>Examines the impact of endoscopist performance (ADR &amp; PSPDR) vs. high-risk polyps on post-colonoscopy colorectal cancer (PCCRC) risk.</li><li>Key finding: Endoscopist performance is a stronger predictor of PCCRC risk in the initial years post-colonoscopy than the presence of high-risk polyps.</li><li>Fun Fact: Colonoscopies can detect polyps smaller than a grain of rice!</li></ul>
                
        <details>
            <summary><strong>Background and Aims</strong></summary>
            <div>
                <ul><li>Current post-polypectomy guidelines base surveillance intervals solely on resected polyp features.</li><li>ADR and PSPDR have an inverse relationship with PCCRCs, but are not considered in surveillance intervals.</li><li>This study aims to compare the impact of endoscopist&#x27;s ADR/PSPDR with polyp characteristics on PCCRC development within 3 years.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>Analyzed colonoscopy data (2014-2020) from the Dutch CRC screening program (FIT-based).</li><li>Individuals categorized: high-risk polyps vs. no/low-risk polyps.</li><li>Association between 3-year PCCRC risk and high-risk polyps, ADR, or PSPDR studied using Cox proportional hazard regression.</li></ul>
                
        <details>
            <summary><strong>Study Population</strong></summary>
            <div>
                <ul><li>Included individuals aged 55-75 years participating in the Dutch FIT-based CRC screening program (2014-2020).</li><li>FIT positivity threshold: ≥15ug/g (first 6 months), increased to ≥47ug/g after.</li><li>Endoscopists accredited, must achieve ADR ≥40% and polyp retrieval/removal rate ≥90%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Study Endpoints and Outcome Definitions</strong></summary>
            <div>
                <ul><li>Primary endpoint: Relative risk of PCCRC within 3 years after complete colonoscopy (no CRC found).</li><li>Compared PCCRC risk based on endoscopist&#x27;s ADR/PSPDR vs. high-risk polyps.</li><li>Secondary endpoint: 3-year incidence rate of PCCRC in subgroups stratified by polyp risk and endoscopist performance (high/medium/low ADR/PSPDR).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Definitions</strong></summary>
            <div>
                <ul><li>ADR: Proportion of colonoscopies with ≥1 adenoma detected.</li><li>PSPDR: Proportion of colonoscopies with ≥1 serrated polyp proximal to the descending colon detected.</li><li>PCCRC: CRC diagnosed ≥6 months after complete colonoscopy (no CRC found), within 36 months of baseline colonoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Classification</strong></summary>
            <div>
                <ul><li>High-risk polyps: Adenomas ≥10 mm, high-grade dysplasia, or ≥5 low-risk adenomas; serrated polyps ≥10 mm, dysplasia, or traditional serrated adenomas.</li><li>No/low-risk polyps: All other polyp findings or no polyps detected.</li><li>ESGE guideline recommends 3-year follow-up for high-risk, no surveillance for no/low-risk.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Inclusion/Exclusion Criteria</strong></summary>
            <div>
                <ul><li>High-quality colonoscopies w/ adequate bowel prep and complete procedures included.</li><li>Exclusion: Follow-up &lt;6 months, further endoscopic treatment (EMR/ESD), CT-colonography referral, early polypectomy scar evaluation, cancer diagnosis at baseline or within 6 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Data Collection</strong></summary>
            <div>
                <ul><li>Colonoscopy data from Dutch CRC screening database.</li><li>CRC data from Dutch Cancer Registry.</li><li>Histopathology data from PALGA (Dutch nationwide histopathology database).</li><li>Data linked using Dutch citizen service numbers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Statistical Analyses</strong></summary>
            <div>
                <ul><li>Shared frailty Cox regression (endoscopist as random effect) to evaluate PCCRC risk within 3 years.</li><li>HRs with 95% CIs presented.</li><li>Independent variables: ADR/PSPDR (continuous), presence of high-risk polyps.</li><li>Models adjusted for age and sex.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Results</strong></summary>
            <div>
                <ul><li>277,555 colonoscopies included for ADR/PSPDR calculation (441 endoscopists).</li><li>Median PSPDR: 11.9% (IQR 8.3-15.8). Median ADR: 66.3% (IQR 61.4-69.9).</li><li>202 PCCRCs diagnosed within 36 months among 239,217 individuals (2.62 cases per 10,000 PYFU).</li></ul>
                
        <details>
            <summary><strong>Endoscopist Categories</strong></summary>
            <div>
                <ul><li>Low ADR: &lt;63%. Medium ADR: 63-68.7%. High ADR: ≥68.7%.</li><li>Low PSPDR: &lt;9.5%. Medium PSPDR: 9.5-14.5%. High PSPDR: ≥14.5%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PCCRC Incidence</strong></summary>
            <div>
                <ul><li>164,928 individuals: no/low-risk polyps. 74,289 individuals: high-risk polyps.</li><li>PCCRC incidence: 2.54 cases per 10,000 PYFU (high-risk) vs. 2.66 (no/low-risk).</li><li>Median time to cancer diagnosis: 24 months in both groups.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Association with ADR/PSPDR</strong></summary>
            <div>
                <ul><li>Univariate analysis: ADR &amp; PSPDR inversely associated with PCCRC risk within 3 years.</li><li>Multivariate analysis: 1% ↑ in ADR → 6% ↓ in PCCRC risk (HR 0.94; CI 0.92-0.96). 1% ↑ in PSPDR → 8% ↓ in PCCRC risk (HR 0.92; CI 0.89-0.95).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Stratified Analysis</strong></summary>
            <div>
                <ul><li>Individuals w/ no/low-risk polyps examined by high ADR endoscopists: lowest PCCRC incidence (1.16 cases per 10,000 PYFU).</li><li>Individuals w/ high-risk polyps examined by low ADR endoscopists: highest PCCRC incidence (4.18 cases per 10,000 PYFU).</li><li>No/low-risk polyps + low ADR endoscopist: HR of PCCRC 2.11 (1.21-3.65) compared to high-risk polyps + high ADR endoscopist.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sensitivity Analysis</strong></summary>
            <div>
                <ul><li>Excluding 2014 data (different FIT threshold): Results consistent.</li><li>≥20mm threshold for high-risk polyps: ↑ PCCRC 3-year incidence compared to low-risk/no polyps.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>Endoscopist&#x27;s ADR/PSPDR significantly impacts PCCRC risk within 3 years; high-risk polyps do not.</li><li>Individuals w/ no/low-risk polyps examined by low ADR/PSPDR endoscopists have ≥2x higher PCCRC risk vs. high-risk polyps examined by high ADR/PSPDR endoscopists.</li><li>Current guidelines would advise surveillance for the latter, but not the former.</li></ul>
                
        <details>
            <summary><strong>Comparison to Previous Studies</strong></summary>
            <div>
                <ul><li>Prior studies (long-term data) showed higher cancer risk in individuals examined by low ADR endoscopists and those with high-risk polyps.</li><li>This study&#x27;s focus on the first 3 years suggests endoscopist quality is more relevant short-term, while polyp features may play a greater role long-term.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implications for Surveillance</strong></summary>
            <div>
                <ul><li>Incorporate endoscopist&#x27;s ADR/PSPDR into prediction models alongside polyp features.</li><li>Establish quality assurance programs with accreditation, monitoring ADR, PSPDR, CIR, BBPS, and withdrawal time.</li><li>Raise ADR benchmark (currently 40% in the Netherlands) based on evidence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Alternative Strategies</strong></summary>
            <div>
                <ul><li>Distal attachment devices, longer withdrawal times, second observer can improve ADRs.</li><li>These are more practical in the short-term for settings where implementing a quality assurance program is challenging.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Potential confounders (endoscopist demographics, participant risk factors) not analyzed.</li><li>High FIT cut-off, high baseline ADR/PSPDR limit generalizability.</li><li>PCCRC definition restricted to 36 months.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Individual&#x27;s PCCRC risk in initial years primarily influenced by endoscopist&#x27;s ADR/PSPDR, not high-risk polyps.</li><li>Reduce PCCRCs by monitoring and auditing endoscopist quality indicators, besides risk-stratified surveillance intervals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Tables and Figures Summary</strong></summary>
            <div>
                <ul><li>Table 1: Baseline characteristics of colonoscopies included for ADR/PSPDR and PCCRC analysis.</li><li>Table 2: Shared frailty Cox regression analysis of ADR/PSPDR and high-risk polyps on PCCRC risk.</li><li>Figures 1 &amp; 2: PCCRC incidence stratified by endoscopist performance (ADR/PSPDR) and presence of high-risk polyps.</li></ul>
                
        <details>
            <summary><strong>Table 1: Baseline Characteristics</strong></summary>
            <div>
                <ul><li>Includes data on age, sex, PCCRC location and stage, follow-up time, number of endoscopists, median colonoscopies performed, median PSPDR/ADR, and distribution of endoscopists by ADR/PSPDR categories.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 2: Cox Regression Analysis</strong></summary>
            <div>
                <ul><li>Shows univariate and multivariate hazard ratios for PCCRC risk based on ADR/PSPDR and presence of high-risk polyps, adjusted for age and gender.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Figures 1 &amp; 2: PCCRC Incidence</strong></summary>
            <div>
                <ul><li>Illustrate PCCRC incidence per 10,000 person-years of follow-up, stratified by endoscopist performance (low vs. high ADR/PSPDR) and presence/absence of high-risk polyps.  Includes hazard ratios comparing different subgroups.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>What You Need to Know</strong></summary>
            <div>
                <ul><li>Current guidelines don&#x27;t consider ADR/PSPDR in post-polypectomy surveillance.</li><li>High-risk polyps at baseline not associated with PCCRC risk within 3 years; ADR/PSPDR strongly associated.</li><li>Emphasizes monitoring endoscopist quality indicators for PCCRC prevention, not solely risk-stratifying based on polyp features.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
